Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Non Operating Income (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Non Operating Income data on record, last reported at -$882000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income rose 81.59% year-over-year to -$882000.0; the TTM value through Dec 2025 reached -$5.7 million, up 46.52%, while the annual FY2025 figure was -$5.7 million, 46.52% up from the prior year.
  • Non Operating Income reached -$882000.0 in Q4 2025 per VRCA's latest filing, up from -$3.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.1 million in Q4 2021 and bottomed at -$4.8 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$1.1 million, with a median of -$1.1 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: skyrocketed 103.21% in 2023, then tumbled 13791.43% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $3.1 million in 2021, then plummeted by 135.11% to -$1.1 million in 2022, then surged by 103.21% to $35000.0 in 2023, then crashed by 13791.43% to -$4.8 million in 2024, then soared by 81.59% to -$882000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$882000.0 in Q4 2025, -$3.2 million in Q3 2025, and -$1000.0 in Q2 2025.